BLRX ready to show it's strategy.....one that PFE & LLY are following......I am impressed:
December 12, 2014
BioLineRx to host Investor/Analyst Breakfast in New York from 8am to 10am EST on December 12, 2014 to present the Company's 2015 clinical development strategy for BL-8040 (AML and other hematological indications)
Keynote presentation to be given by Dr. Jorge Cortes, Distinguished Professor of Leukemia Research at the MD Anderson Cancer Center in Houston, Texas
Convene Conference Center
730 Third Avenue (between 45th and 46th Streets)
New York, NY 10017
Not only are the presenting data at ASH in same indications that PFE & LLY are targeting, but read this note from Roth:
10 Nov 12:00 [BLRX] Roth Capital reiterates Buy rating, price target $8 - Firm believes BioLine is on the verge of significant news flow, which they believe will provide further boost to its U.S. visibility. While the company is not vocal on the topic, firm believes the upcoming data catalysts across the pipeline will be instrumental in potential partnering discussions. The company's broad pipeline of products also allows for spreading out of the underlying risk to valuation.
Finally the bottom is reached.
Regulus Therapeutics (RGLS) is not winning many converts among hepatitis C doctors. An injectable treatment option is too little too late in an era of convenient pills, doctors say. RA Capital's representative asked every doctor at the meetings if a single injection cure for hepatitis C would be an attractive option -- an unrealistic hypothetical, but an understandable question coming from RA Capital given the hedge fund bought a huge chunk of Regulus' recent financing.
I agree with this poster. I called the sales line today. They said they don't sell wearable cameras. Not only that, that said they had no increase in sales due to Ferguson, but they can install home security systems through a 3rd party. LOL Longs here are morons.
$ARIA BMO $14 PT says underappreciated value in Iclusig. Scripts have reached prior peak levels. Large pharma maybe interested
Friday night special. "Competitors with larger customer base and greater market visibility, such as Alibaba Group ( "Alibaba"), Tencent Holdings Limited ("Tencent") and Baidu, Inc. ("Baidu"), recently launched their respective internet-based financial platform which provides financial services similar to that of Yinglibao. In the future,
banks and fund management companies may also enter this market and offer similar services to customers. Because of such expected influx of new market entrants, competition in this industry may become more intense. Many of our new competitors, especially Alibaba, Tencent and Baidu, have greater financial and marketing resources than we do. Thus, we may not be able to compete effectively or provide a compelling service alternative for potential customers. Our financial results may suffer as a result."
MOBI has been working over a year to deliver a quarter like this. To me, they key is the 30% quarter to quarter revenue growth & 50% plus smartphone growth. Guidance is huge. The reason why is MOBI is starting to scale it's model....the PR specifically says they signed BIDU & QIHU as partners. What the PR does not say is anything about BABA, which an analyst think they will sign. This stock is undervalued to it's peers. This is finally a report you can latch onto.
Temasek held 1 million shares in Cheetah Mobile in May after the IPO, according to data compiled by Bloomberg at the time. Yesterday’s filing shows it owned 603,764 shares at the end of June, indicating it sold 396,236 shares. The share price gained 52 percent until the end of June.
Right....it's not on google play rankings, and have always been on google play. People are getting fooled here. They have no choice but to warn on the call, watch.
04 Mar 13:29 [CAMT] Files $50M mixed securities shelf - filing (40% of market cap) - Unless otherwise indicated in any accompanying prospectus supplement, we currently intend to use the net proceeds from the sale of the securities offered pursuant to this prospectus for general corporate purposes and working capital requirements. Pending use of the proceeds, we intend to invest the proceeds in portfolios of investment grade corporate and government securities. - Follow up: In addition, the shelf registration, when declared effective, will permit a selling shareholder of Camtek to offer and sell up to 6,000,000 of Camtek's ordinary shares. All net proceeds from the sale of such ordinary shares by the selling shareholder will be received by the selling shareholder
$CAMT confirmed S-3 is effective. It's cash flow was negative too for QTR. If you like the stock buy it on the offering which is coming
Idiots! Buy, buy, buy!
Adam Gefvert, CFA @Shiningboy 29m $BIOF is gonna get diluted at $5 per share. People are actually paying double what they can buy in the dilution?